Podcasts
Listen to the latest hemonc news from international experts
The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), Johnson & Johnson (Gold), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
The evolving role of BTK inhibitors in CLL
This VJHemOnc podcast explores the evolving role of BTK inhibitors in chronic lymphocytic leukemia (CLL). Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, Alfred Hospital and Monash University, Melbourne, Australia, discusses long-term SEQUOIA trial (NCT03336333) findings and extended follow-up from the ALPINE study (NCT03734016) comparing zanubrutinib with ibrutinib in relapsed/refractory (R/R) disease.
Kerry Rogers, MD, The Ohio State University, Columbus, OH, reviews continuous BTK inhibitor therapy and resistance mechanisms, while Romain Guièze, MD, PhD, CHU Clermont Ferrand, Clermont Ferrand, France, discusses the STAIR trial (NCT04963946) evaluating acalabrutinib discontinuation in older, frail patients. To conclude, Jennifer Woyach, MD, The Ohio State University, Columbus, OH, highlights a Phase I trial (NCT04775745) investigating rocbrutinib, and the Phase III BRUIN-CLL314 trial (NCT05254743) results. Finally, Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the potential of pirtobrutinib, a non-covalent BTK inhibitor, in CLL.
Date: 1st May 2026
